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ABSTRACT
Aims: To evaluate the effect of rapamycin (RAPA) and
dexamethasone (DEX) on the production of IL-17 and IFN-
c by peripheral blood mononuclear cells (PBMCs) from
Vogt–Koyanagi–Harada (VKH) patients and healthy
individuals.
Methods: Blood samples were drawn from 10 active
VKH patients and 10 healthy individuals. PBMCs were
cultured with or without anti-CD3 and anti-CD28
antibodies in the presence or absence of different
concentrations of RAPA or DEX for 72 h. IL-17 and IFN-c
concentrations in the supernatants were measured by
enzyme-linked immunosorbent assay (ELISA).
Results: The expression of IL-17 and IFN-c was
significantly increased in active VKH patients compared
with that in healthy controls. Both RAPA and DEX were
able to significantly inhibit the production of IL-17 and IFN-
c by PBMCs from patients and healthy controls. RAPA
was able to completely inhibit IL-17 production at a
dosage of 10 ng/ml but only partially suppressed IFN-c
production even at a much higher concentration
(1000 ng/ml). DEX inhibited the production of both IL-17
and IFN-c by approximately 70%.
Conclusions: This study indicates that both RAPA and
DEX inhibit the production of IL-17 and IFN-c by PBMCs.
RAPA is much stronger in inhibiting the production of IL-
17 than DEX.
Vogt–Koyanagi–Harada (VKH) syndrome is char-
acterized by a panuveitis frequently associated
with headache, pleocytosis, skin vitiligo, alopecia
and inner ear disturbances. It is considered an
autoimmune disease.1 Previous studies have sug-
gested that IFN-c is involved in the pathogenesis of
experimental autoimmune uveitis (EAU) and
human uveitis.2 3 Recent studies have shown that
IL-17 is also involved in the pathogenesis of certain
autoimmune diseases including VKH syndrome.4 5
Rapamycin (RAPA) is a newly developed immu-
nosuppressive agent and has been used for the
prevention and treatment of graft rejection,
coronary artery disease and certain autoimmune
disorders experimentally or clinically.6 7 It has been
shown that RAPA exerts its action primarily via
suppression of IL-2 and other growth factors at the
late G1 phase.8 9 Glucocorticoids are commonly
used in the treatment of autoimmune diseases
including VKH syndrome. It has been demon-
strated that glucocorticoids exert their role through
multiple mechanisms including inhibition of a
variety of cytokines such as IL-2, IL-6, TNF-a and
IFN-c.10 11 Whether RAPA and glucocorticoids
could also inhibit IL-17 production is not yet clear
and therefore was the subject of the study
presented here. Our results showed that both
RAPA and dexamethasone (DEX) inhibited the
production of IL-17 as well as IFN-c. More
importantly, we found that RAPA was much
stronger in inhibiting IL-17 than DEX.
MATERIALS AND METHODS
Patients
Ten patients with VKH syndrome (five men, five
women, with an average age of 36.5) and 10
healthy individuals (six men, four women, with an
average age of 41) were included in this study. The
diagnosis of VKH syndrome was made according
to the revised diagnostic criteria for VKH syn-
drome.12 All patients showed active recurrent
intraocular inflammation as evidenced by mutton
fat keratic precipitates and cells in the anterior
chamber. These patients also showed a sunset
glow fundus and Dalen–Fuchs nodules. The
extraocular findings included tinnitus (50%),
poliosis (40%), alopecia (40%), vitiligo (30%) and
dysacusis (20%). None of the patients received
immunosuppressive drugs for at least 1 week
before blood sampling. All procedures followed
the tenets of the Declaration of Helsinki, and
informed consent was obtained from all patients
and control subjects.
Cell isolation and culture
Mononuclear cells were isolated from heparinized
blood by Ficoll-Hypaque-gradient centrifugation.
For determination of IL-17, IFN-c and IL-13
production, PBMCs were cultured with or without
anti-CD3 (OKT3, 5 mg/ml) (eBioscience, San
Diego, California) and anti-CD28 antibodies
(1 mg/ml) (eBioscience) in the presence or absence
of RAPA (1, 10, 50, 100, 500, 1000 ng/ml) (Sigma,
St Louis, Missouri), which was diluted as below, or
DEX (1, 10, 50, 100, 500, 1000 ng/ml) (Sigma)
respectively for 72 h at a concentration of 26106
cells/ml. RAPA was diluted in dimethyl sulfoxide
(DMSO) (Sigma) and stored at 220uC in the dark.
RAPA was finally diluted with RPMI1640 to the
aforementioned concentrations and used for the
experiments. PBMCs cultured alone served as
negative controls and those cultured with DMSO
(5 mg/ml) in the presence of anti-CD3 and anti-
CD28 antibodies as DMSO controls. Trypan Blue
dyeing was used to evaluate cell viability after
72 hours’ culture. An additional experiment was
performed to investigate the influence of RAPA
and DEX on the production of IL-17 and IFN-c by
PBMCs upon stimulation with four concentrations
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of anti-CD3 antibody (10 ng/ml, 100 ng/ml, 1 mg/ml and 5 mg/
ml).
Measurement of IL-17, IFN-c and IL-13 by ELISA
For determination of IL-17, IFN-c and IL-13 production, the
supernatants obtained from the aforementioned cell cultures
were collected and used for analysis of these cytokines. Duoset
ELISA Development kit (R&D system, Minneapolis,
Minnesota) was used for this study. The detection limits were
15.625, 15.625 and 93.75 pg/ml for IL-17, IFN-c and IL-13,
respectively.
Statistical analysis
The Student t test was used for comparison of two independent
groups of observations. p Values below 0.05 were considered
statistically significant.
RESULTS
IFN-c in the supernatants of unstimulated PBMCs (negative
controls) was barely detectable in both VKH patients and
healthy controls. IL-17 in the supernatant of unstimulated
PBMCs is detectable in seven out of 10 patients with active 10
VKH syndromes and in five out of 10 healthy controls. The
concentration of IL-17 in patients (83.46 (SD 17.96) pg/ml) is
significantly higher than that in controls (46.1 (20.15) pg/ml)
(p,0.05). A significantly increased production of IL-17 and IFN-
c was observed upon anti-CD3 and anti-CD28 antibody
stimulation in the tested samples (both p,0.001). Moreover,
the expression of IL-17 and IFN-c was significantly increased in
active VKH patients compared with that in healthy controls
(p,0.001; p = 0.001, respectively) (fig 1A,B).
RAPA caused a significant reduction in IL-17 in both VKH
patients and healthy controls. The production of IL-17 was
almost totally blocked (.97%) by RAPA at a dosage of 10 ng/ml
(p,0.001) (fig 2A). RAPA was also able to inhibit the
production of IFN-c. However, it inhibited the IFN-c produc-
tion up to approximately 80% in VKH patients even at a high
RAPA concentration (1000 ng/ml) (fig 2B).
The study on influence of RAPA and DEX on the production
of IL-17 and IFN-c by PBMCs stimulated with different
concentrations of anti-CD3 antibody showed a similar result.
RAPA (10 ng/ml) was able to completely inhibit the production
of IL-17 at any one of the four concentrations of anti-CD3
antibodies, whereas it only partially inhibited the IFN-c
production. DEX only partly inhibited the production of both
IL-17 and IFN-c no matter which concentration of anti-CD3
antibody was used.
No influence was found on the production of IL-17 and IFN-c
by PBMCs when cultured with DMSO alone (fig 2A,B). After a
72 h culture with different concentrations of RAPA or DMSO in
the presence of anti-CD3 and anti-CD28 antibodies, the results
showed that about 85% of PBMCs were still viable in both VKH
patients and healthy controls (fig 3). IL-13 was not detectable in
cell cultures from both VKH patients and controls (data not
shown).
DEX was also able to significantly inhibit the production of
IL-17 and IFN-c by PBMCs stimulated with anti-CD3 and anti-
CD28 antibodies (both p = 0.001). A gradually increased
inhibition was observed from 1 to 100 ng/ml of DEX
(figs 4A,B, 5A,B). The maximal inhibition of DEX was about
70% in VKH patients. Much higher concentrations (more than
100 ng/ml) of DEX did not increase its inhibitory effect
(fig 4A,B). The results for the DEX experiment also showed
that the concentrations used did not influence the viability of
the PBMCs (fig 3).
Comparing the effect of RAPA and DEX on the production of
IL-17 and IFN-c, we found that the former was much stronger
than the latter in terms of both volume concentrations and
mole concentrations (data not shown).
DISCUSSION
The present study showed that the expression of IL-17 and IFN-
c was significantly increased in VKH patients with active
uveitis. RAPA and DEX could effectively inhibit the production
of both IL-17 and IFN-c. Importantly, RAPA was shown to be
much stronger in inhibiting the production of these two
cytokines.
Previous studies suggest that IFN-c, a classical Th1 cytokine,
plays an important role in the development of certain
autoimmune and inflammatory diseases including VKH syn-
drome.13 14 Recent studies from our laboratory revealed that IL-
17 was also actively involved in this disease.5 The present study
is an extension of our earlier findings in a new group of VKH
patients and confirms our earlier observations showing that the
expression of both IL-17 and IFN-c is increased in VKH.
RAPA is a novel immunosuppressive agent. It has been
demonstrated that RAPA can effectively suppress the produc-
tion of cytokines including IL-2 and IL-12.15 In this study we
examined whether RAPA could inhibit the production of IL-17
Figure 1 Production of IL-17 and IFN-c by peripheral blood
mononuclear cells (PBMCs) upon stimulation with or without anti-CD3
and anti-CD28 antibodies. Isolated PBMCs were cultured with or without
anti-CD3 and anti-CD28 for 72 h. Levels of IL-17 (A) and IFN-c (B) in
supernatants of PBMCs from Vogt–Koyanagi–Harada (VKH) patients
(n = 10) and healthy controls (n = 10) were determined by ELISA. Data
are expressed as means (SD).
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(Th17 cells) and IFN-c (Th1 cells) in vitro. The results showed
that it could effectively inhibit the production of both IL-17 and
IFN-c by PBMCs cultured for a period of 72 h. However,
suitable doses with excellent inhibitory effects at different
culture time points are as yet unknown. More studies are
needed to clarify this issue. The potent suppressive role of RAPA
may explain the inhibition on the induction of EAU previously
reported by Roberge et al.16 Previous findings also revealed that
IFN-c played a role in the development of EAU. A recent study
reported by Amadi-Obi et al17 showed that IL-17 was also
involved in the development of EAU. Taken together, the
above-mentioned results suggest that the inhibiting effect of
RAPA on EAU may be due to its suppression of both IL-17 and
IFN-c. Interestingly, we found that RAPA almost completely
blocked IL-17 production at 10 ng/ml. This concentration of
RAPA has also been reported by others to effectively inhibit the
production of certain cytokines such as IL-2 and IL-10.18 19
Glucocorticoids are classical immunosuppressive agents and
have been widely used for the treatment of autoimmune
diseases. It has been demonstrated that they can inhibit the
production of a number of cytokines including IL-2, IL-4 and
IFN-c.20 In this study, we investigated its inhibitory effect on
the production of IL-17 as well as IFN-c in vitro. The result
showed that DEX equally inhibited these two cytokines. Our
results on IFN-c are generally consistent with those observed in
healthy individuals, patients with asthma and experimental
studies in mice.20–22 The effect of DEX on IL-17 found in our
study is similar to that reported by Suzuki et al.23 They found
that the expression of IL-17 was significantly attenuated by the
treatment of mice with DEX.
Comparing the effect of DEX and RAPA on IL-17 and IFN-c,
we found the following results. First, both RAPA and DEX
inhibited Th1 cells and Th17 cells. Second, RAPA had a stronger
role in inhibiting both cytokines than DEX in terms of both
volume concentrations and mole concentrations. Third, RAPA
was found to have a stronger role in suppressing IL-17 than
inhibiting IFN-c. All these results suggest that RAPA may be
more effective in the treatment of diseases mediated by IL-17
and IFN-c than DEX. More importantly, RAPA may be more
suitable for diseases mediated predominantly by IL-17. Our
results may partially explain the better results of RAPA in
treating glucocorticoid-non-sensitive patients with autoim-
mune diseases including systemic lupus erythematosus (SLE)
and rheumatoid arthritis (RA).24 25
Our results also showed that IL-13, a typical cytokine for Th2
cells, was not detectable in patients with VKH syndrome. In
vitro experiments showed that both RAPA and DEX did not
influence the expression of this cytokine (data not shown).
Therefore, it is unlikely that RAPA and glucocorticoids exert
their roles via upregulating Th2 cytokines.
Figure 2 Effect of rapamycin (RAPA) on the production of IL-17 and
IFN-c in vitro. Isolated peripheral blood mononuclear cells from Vogt–
Koyanagi–Harada (VKH) patients and healthy controls were cultured with
anti-CD3 and anti-CD28 antibodies at a density of 26106 cells/ml in the
presence of different concentrations of RAPA (1, 10, 50, 100, 500,
1000 ng/ml) for 72 h. The levels of these two cytokines in the
supernatant were detected using ELISA analysis. (A) The inhibiting rate
of RAPA on the production of IL-17 is over 97% at 10 ng/ml in VKH
patients. (B) The inhibiting rate of RAPA on the production of IFN-c is
about 80% at 10 ng/ml in VKH patients. Data are expressed as means
(SD).
Figure 3 Cell viability of peripheral blood mononuclear cells assessed
using Trypan Blue, with baseline cell viabilities in the absence of added
drugs. The data shown in this figure are representative of three
independent experiments. DEX, dexamethasone; RAPA, rapamycin; VKH,
Vogt–Koyanagi–Harada.
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In conclusion, our study showed that both RAPA and DEX
significantly inhibited the Th17 cells and Th1 cells, whereas
they did not influence the viability of these cells. More
importantly RAPA was much stronger in suppressing both
Th17 cells and Th1 cells in vitro. This study suggests that RAPA
may be an effective drug in the treatment of diseases mediated
by Th17 cells and Th1 cells. However, our study did not answer
the question as to whether both drugs could inhibit cellular
proliferation or CD25 expression. More studies are needed to
clarify these issues.
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